Dillon & Associates’s Pfizer PFE Stock Holding History

Dillon & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,754	Closed	-$221K	–	82
2021 Q4	$221K	Buy	+3,754	New	+$186K	0.04%	74

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dillon & Associates's PFE Position: Q1 2022 in Review

Dillon & Associates sold out of Pfizer (PFE) in Q1 2022, closing a stake of 3,754 shares — an estimated $221K sold.

Dillon & Associates first reported a position in PFE in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Dillon & Associates reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Dillon & Associates sold 3,754 Pfizer shares in Q1 2022, an estimated $221K.
Dillon & Associates first reported a position in Pfizer in Q4 2021 and held it in 1 quarter.
Dillon & Associates's Pfizer position peaked at $221K in Q4 2021.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Dillon & Associates's 13F filing for Q1 2022, filed 6 May 2022.